



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/010,942	12/06/2001	Guriq Basi	ELN-002

000959
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109

CONFIRMATION NO. 5594

FORMALITIES LETTER



OC000000008658514

Date Mailed: 08/21/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Guriq Basi, *et al.*

Serial No.: 10/010942

Filed: December 6, 2001

For: *Humanized Antibodies That Recognize
Beta Amyloid Peptide*

Attorney Docket No.: ELN-002

Group Art Unit: 1645

Examiner: Not Yet Assigned

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on the date set forth below.

September 16, 2002

Date of Signature and of Mail Deposit

By:

Debra L. Milasincic, Esq.

Registration No. 46,931

Attorney for Applicants

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed from the Patent Office on August 21, 2002, we enclose herewith a diskette which contains a Substitute Sequence Listing in computer readable form as required by 37 C.F.R. 1.821(e). Also enclosed is

a statement that the content of the Substitute Sequence Listing (pages 1-22) submitted with the above-referenced patent application and the computer readable copy are the same as required under 37 C.F.R. 1.821(f). Also enclosed is a copy of the Notice to Comply for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures. No new matter has been added.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Debra J. Milasincic, Esq.

Registration No. 46,931

Attorney for Applicants

28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: September 16, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Guriq Basi, *et al.*

Serial No.: 10/010942

Filed: December 6, 2001

For: *Humanized Antibodies That Recognize
Beta Amyloid Peptide*

Attorney Docket No.: ELN-002

Group Art Unit: 1645

Examiner: Not Yet Assigned

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202

**TRANSMITTAL LETTER FOR DISKETTE CONTAINING
SUBSTITUTE SEQUENCE LISTING**

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the patent application filed on December 6, 2001. The Sequence Listing complies with the requirements of 37 C.F.R. §1.821. The material on this diskette is identical in substance to the sequence listing appearing on pages 1-22 of the Sequence Listing which is submitted herewith, as required by 37 C.F.R. §1.821(f). The computer readable form of the sequence listing contained on the enclosed diskette is understood to comply with the requirements of §1.824(d).

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on:

September 16, 2002

Date

Debra J. Milasincic, Esq., Registration No. 46,931

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

Date: **September 16, 2002**